Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe pers...

por Beeh, Kai-Michael, LaForce, Craig, Gahlemann, Martina, Wenz, Arne, Toorawa, Robert, Fležar, Matjaž
Publicado 2015

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β(2)-agonist, in patients with asthma: results of a parallel-group study and a crossover study

por O’Byrne, Paul M., D’Urzo, Tony, Beck, Ekkehard, Fležar, Matjaž, Gahlemann, Martina, Hart, Lorna, Blahova, Zuzana, Toorawa, Robert, Beeh, Kai-Michael
Publicado 2015